Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag

Table 1

Baseline data of patients.

Characteristics	Study group	Control group
Gender
Male	16	14	0.8483	0.3570
Female	16	22
Age (years)
>60	19	19	0.2991	0.5845
≤60	13	17
Smoking history
Yes	18	21	0.0301	0.8623
No	14	15
TNM stage
IIIC	9	12	0.2153	0.6426
IV	23	24
Number of tumor
Solitary	7	6	0.2972	0.5856
Multiple	25	30
Histological type
Adenocarcinoma	20	22	0.2183	0.6404
Squamous cell carcinoma	10	14
Line of medication
First-line	13	23	3.680	0.0551
Second-line	19	13
Brain metastases
Yes	2	3	0.1079	0.7425
No	30	33